SELLAS Life Sciences Group, Inc. (SLS)
SELLAS develops cancer immunotherapy and targeted drug candidates for blood cancers and solid tumors. It last closed at $19.18 on Nov 17, up 156.76% on the day. Over the past 90 days StreetAlpha recorded 5 whale options trades in SLS, 40% of them bullish and 60% bearish. In the past 30 days there were 2 dark pool prints totaling $795K, the largest $457K.
Key Stats
Last 12 monthsNot reported for this period.
From SLS's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Technical Analysis
The stock is 48% above its 20 day and 43% above its 50 day average. It is 54% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 77), overbought. The nearest support is the Pivot S1 at $15.64, and the nearest resistance the Pivot at $20.26.
| RSI (14) | 76.63 | Overbought above 70 | Overbought |
| MACD | -0.07 | Above its signal line | Bullish |
| Stochastic | 29.2 | Middle of its range | Neutral |
| ADX (14) | 28.6 | Trending up | |
| Williams %R | -32.2 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | 353.1 | Oversold below −100, overbought above 100 | Overbought |
| Rate of change | +116.2% | Change over 10 sessions | Bullish |
| ATR (14) | $2.15 | Typical daily range, 11.2% of price |
| RSI (14) | 67.74 | Strong, overbought above 70 | Neutral |
| MACD | 1.00 | Below its signal line | Bearish |
| Stochastic | 30.4 | Middle of its range | Neutral |
| ADX (14) | 37.2 | Trending up | |
| Williams %R | -32.2 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | 236.2 | Oversold below −100, overbought above 100 | Overbought |
| Rate of change | +66.1% | Change over 10 sessions | Bullish |
| ATR (14) | $3.15 | Typical daily range, 16.4% of price |
What happened before
See how SLS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How SLS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2008.
Whale Options Flow
90DNo whale options trades in SLS in the last 90 days.
Dark Pool
30DSLS Institutional Ownership
Full report →- ▲140 buying vs 62 selling
- ▼Held by funds -1.0 pts
- ▲Funds holding +24
- ▼Superinvestors: 0 added, 1 cut
- ▲Put/call 4.45 to 1.67
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 218 | 194 | +12.4% |
| In funds' top 10 | 0 | 2 | −100.0% |
| Held by funds | 35.4% | 36.4% | −1.0 pts |
| New / increased | 47 / 93 | 59 / 78 | +2.2% |
| Reduced / sold out | 39 / 23 | 26 / 28 | +14.8% |
| Put/call ratio | 1.67 | 4.45 | −62.5% |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether SLS is in one of them and how their past SLS trades turned out.
SLS News Tone and Price
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered SLS in an article yet. Here's the latest on the wider market.
About SELLAS Life Sciences Group
SELLAS is a clinical stage biopharmaceutical company based in New York that develops treatments for cancer. Its lead candidate, galinpepimut-S, is an immunotherapy that targets the WT1 protein, which is found in many types of cancer, including blood cancers such as acute myeloid leukemia. The company is also developing tambiciclib, a small molecule drug that inhibits CDK9, for patients with blood and solid cancers. Both candidates are in clinical trials.
- Headquarters
- New York, NY
- Founded
- 2006
- Website
- galenabiopharma.com ↗
